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The PREVAIL TrialDavid R. Holmes JR, MD,* Saibal Kar, MD,y Matthew J. Price, MD,z Brian Whisenant, MD,x Horst Sievert, MD,k
Shephal K. Doshi, MD,{ Kenneth Huber, MD,# Vivek Y. Reddy, MD**ABSTRACTro
a
sBACKGROUND In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in
Patients With Atrial Fibrillation) trial that evaluated patients with nonvalvular atrial ﬁbrillation (NVAF), left atrial appendage
(LAA) occlusion was noninferior to warfarin for stroke prevention, but a periprocedural safety hazard was identiﬁed.
OBJECTIVES The goal of this study was to assess the safety and efﬁcacy of LAA occlusion for stroke prevention in
patients with NVAF compared with long-term warfarin therapy.
METHODS This randomized trial further assessed the efﬁcacy and safety of the Watchman device. Patients with NVAF
who had a CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and previous stroke/
transient ischemic attack) score $2 or 1 and another risk factor were eligible. Patients were randomly assigned (in a
2:1 ratio) to undergo LAA occlusion and subsequent discontinuation of warfarin (intervention group, n ¼ 269) or receive
chronic warfarin therapy (control group, n ¼ 138). Two efﬁcacy and 1 safety coprimary endpoints were assessed.
RESULTS At 18 months, the rate of the ﬁrst coprimary efﬁcacy endpoint (composite of stroke, systemic embolism [SE],
and cardiovascular/unexplained death) was 0.064 in the device group versus 0.063 in the control group (rate ratio 1.07
[95% credible interval (CrI): 0.57 to 1.89]) and did not achieve the prespeciﬁed criteria noninferiority (upper boundary of
95% CrI$1.75). The rate for the second coprimary efﬁcacy endpoint (stroke or SE>7 days’ postrandomization) was 0.0253
versus 0.0200 (risk difference 0.0053 [95% CrI: –0.0190 to 0.0273]), achieving noninferiority. Early safety events
occurred in 2.2% of the Watchman arm, signiﬁcantly lower than in PROTECT AF, satisfying the pre-speciﬁed safety per-
formance goal. Using a broader, more inclusive deﬁnition of adverse effects, these still were lower in PREVAIL (Watchman
LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) trial than in PROTECT AF
(4.2% vs. 8.7%; p ¼ 0.004). Pericardial effusions requiring surgical repair decreased from 1.6% to 0.4% (p ¼ 0.027), and
those requiring pericardiocentesis decreased from 2.9% to 1.5% (p ¼ 0.36), although the number of events was small.
CONCLUSIONS In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention or SE >7 days’
post-procedure. Although noninferiority was not achieved for overall efﬁcacy, event rates were low and numerically
comparable in both arms. Procedural safety has signiﬁcantly improved. This trial provides additional data that LAA
occlusion is a reasonable alternative to warfarin therapy for stroke prevention in patients with NVAF who do not have an
absolute contraindication to short-term warfarin therapy. (J Am Coll Cardiol 2014;64:1–12) © 2014 by the American
College of Cardiology Foundation.m the *Mayo Clinic, Rochester, Minnesota; yCedars Sinai Medical Center, Los Angeles, California; zScripps Clinic, La Jolla,
lifornia; xIntermountain Medical Center, Salt Lake City, Utah; kCardiovasculares Centrum, Frankfurt, Germany; {Paciﬁc Heart
titute, Santa Monica, California; #Saint Luke’s Mid America Heart Institute, Kansas City, Missouri; and the **Mount SinaiF
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LAA = left atrial appendage
NOACs = new oral
anticoagulants
NVAF = nonvalvular atrial
ﬁbrillation
SE = systemic embolism
TEE = transesophageal
echocardiography
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2troke prevention in patients with non-
valvular atrial ﬁbrillation (NVAF) has
been the focus of substantial clinical
investigation related to the increasing fre-
quency of this arrhythmia with the aging pop-
ulation, the well-documented relationship
between increasing age and increased stroke,
and the particularly major morbidity/mortal-
ity from cardioembolic stroke (1–5). Tradi-
tional treatment strategies have relied on
chronic anticoagulation, either with warfarinor the newer anticoagulant agents (6–9). Growing in-
formation regarding the central role of left atrial
appendage (LAA) thrombus has led to mechanical
approaches for stroke prevention in this setting.SEE PAGE 13A number of catheter- and surgical-based strategies
have been studied (10–16); with the exception of one
randomized clinical trial (17), the majority of the infor-
mation regarding these approaches has been gathered
from smaller registries (12–16). In the PROTECT AF
(Watchman Left Atrial Appendage System for Embolic
Protection in Patients With Atrial Fibrillation) study,
LAA occlusion was documented to be noninferior to
warfarin for the primary efﬁcacy endpoint of stroke,
cardiovascular death, and systemic embolism (SE)
(17,18). However, several concerns were raised by the
U.S. Food and Drug Administration regarding patient
selection criteria (e.g., inclusion of patients with
CHADS2 [congestive heart failure, hypertension, age
>75 years, diabetesmellitus, and previous stroke/tran-
sient ischemic attack] scores of 1) and acute safety
events, particularly in the early portion of the trial,
and a second trial was recommended (19). To furtheredicine, New York, New York. This studywas sponsored by Atritec
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stroke prevention and to address these concerns, we
performed the PREVAIL (Prospective Randomized
Evaluation of theWatchman LAA Closure Device In Pa-
tients With Atrial Fibrillation Versus Long Term
Warfarin Therapy) trial. (A listing of the PREVAIL
investigator sites is given in the Online Appendix.)
MATERIALS AND METHODS
The multicenter, randomized clinical trial PREVAIL
(NCT01182441) assessed the safety and efﬁcacy of LAA
closure with the Watchman device (Boston Scientiﬁc,
St. Paul, Minnesota) compared with warfarin in pa-
tients with NVAF (paroxysmal, persistent, or perma-
nent) and a CHADS2 score $2. In accordance with
contemporary guidelines for stroke prevention in AF,
patients could be enrolled with a CHADS2 score of 1 if
they also had any of the following higher-risk charac-
teristics: female age $75 years, baseline ejection
fraction $30% but <35%, age 65 to 74 years and either
diabetes or coronary disease, and age $65 years with
congestive heart failure. These inclusion criteria were
meant to include a higher risk group than had been
evaluated in PROTECT AF. Exclusion criteria included
requirement for long-term anticoagulation therapy for
reasons other than AF, contraindication to warfarin or
aspirin, previous stroke/transient ischemic attack
within 90 days of enrollment, symptomatic carotid
disease, or a patent foramen ovale or atrial septal
defect requiring treatment. Patients in whom clopi-
dogrel therapy was indicated were also excluded to
minimize the confounding variable of chronic thieno-
pyridines, which potentially could inﬂuence the inci-
dence of stroke, thromboembolism, or bleeding (20).
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3ischemic stroke, SE, and cardiovascular/unexplained
death. The second was late-ischemic efﬁcacy, a com-
posite of ischemic stroke or SE, excluding the ﬁrst
7 days after randomization. This endpoint had the goal
of evaluating the mechanism by which placement of
the LAAocclusion devicemight improve outcome. This
speciﬁcefﬁcacyendpointcouldthenprovideadditional
information to evaluate the hypothesis that the LAA
is the source of thromboembolism in patients with
NVAF; that hypothesis would be substantiated if local
treatment with occlusion of the LAA was noninferior
to systemic anticoagulation. The third coprimary end-
point was early safety, a composite of all-cause death,
ischemic stroke, SE, or device-/procedure-related
events requiring open cardiovascular surgery or major
endovascular intervention such as surgical treatment
of a pseudoaneurysm between randomization and
within 7 days of the procedure or during the index hos-
pitalization. Percutaneous catheter drainage of peri-
cardial effusions, snaring of the embolized device, and
nonsurgical treatments of access complications were
excluded from this safety endpoint. Each endpoint
was powered separately or had a pre-speciﬁed perfor-
mance goal necessary to achieve success.Implant — 4
Warfarin: dosage to ach
Aspirin: 81 mg while
Clopidogrel
LAA Seal per 45 Day TEE
Warfarin: No
Aspirin: 325 mg*
Clopidogrel: Yes
45 day — 6 Months
Warfarin: No
Aspirin: 325 mg*
Clopidogrel: No
6 Months — 5 Years Wa
FIGURE 1 Medication Guidelines for Subjects in the Device Group
Post-implant protocol-speciﬁed medication requirements and warfarin ce
deﬁned as transesophageal echocardiography (TEE)–documented residu
thrombus on the device. *Recommended dosage. INR ¼ international noOther endpoints included stroke (both ischemic
and hemorrhagic) or SE that resulted in signiﬁcant
disability, death, or all-cause mortality.
RANDOMIZATION AND MASKING. The study, which
included up to 50 investigational sites in the United
States, enrolled up to 475 patients; 407 were enrolled
through randomization, and the remaining patients
were enrolled through the roll-in process. A minimum
of 20% of randomized patients were enrolled in in-
stitutions that had not participated in previous
Watchman studies, and a minimum of 25% of the ran-
domized patients were to be treated by new operators.
After screening, patients meeting the inclusion/
exclusion criteria were randomly assigned (by
computer-generated randomization) to the device in-
tervention or the control group (2:1 ratio). Randomi-
zation was stratiﬁed according to clinical center and
was performed by using a centralized system using
block sizes of 6 (4 interventions and 2 controls). The
centralized computer system was password protected
and accessed by the principal investigator and study
coordinator after the patient gave consent and met
inclusion criteria. Participants and clinicians were not
masked to treatment assignment.5 day
ieve INR 2.0-3.0
 on warfarin
: No
NO LAA Seal per 45 Day TEE
rfarin: Discontinued when seal is adequate
Aspirin:
On warfarin - 81 mg 
Off warfarin - 325 mg* indefinitely
Clopidogrel: No
6 Months — 5 Years
Warfarin: Yes
Aspirin: 81 mg while on warfarin
Clopidogrel: No
45 day — 6 Months
ssation requirements. Aspirin dosage was recommended and seal was
al peridevice ﬂow <5 mm in width and no deﬁnite visible large
rmalized ratio; LAA ¼ left atrial appendage.
TABLE 1 Baseline Demographic Characteristics and Risk Factors (Randomized Subjects)
Device Group
(n ¼ 269)
Control Group
(n ¼ 138) p Value
Characteristics
Age, yrs 74.0  7.4 (269)
(50.0, 94.0)
74.9  7.2 (138)
(53.0, 90.0)
0.260
Height, in 68.4  4.3 (269)
(57.0, 80.0)
68.5  4.0 (138)
(57.0, 78.0)
0.944
Weight, lbs 196.3  44.9 (269)
(106.0, 333.0)
197.1  43.3 (138)
(112.0, 317.0)
0.851
Sex 0.146
Female 87/269 (32.3%) 35/138 (25.4%)
Male 182/269 (67.7%) 103/138 (74.6%)
Race/ethnicity 0.603
Asian 1/269 (0.4%) 1/138 (0.7%)
Black/African American 6/269 (2.2%) 1/138 (0.7%)
White 253/269 (94.1%) 131/138 (94.9%)
Hispanic/Latino 6/269 (2.2%) 5/138 (3.6%)
Native American Indian/Alaskan Native 1/269 (0.4%) 0/138 (0.0%)
Other 2/269 (0.7%) 0/138 (0.0%)
Risk
CHADS2 score (categorical) 0.484
1 21/269 (7.8%) 12/138 (8.7%)
2 137/269 (50.9%) 62/138 (44.9%)
3 65/269 (24.2%) 36/138 (26.1%)
4 33/269 (12.3%) 21/138 (15.2%)
5 12/269 (4.5%) 7/138 (5.1%)
6 1/269 (0.4%) 0/138 (0.0%)
CHADS2 score (continuous) 2.6  1.0 (269)
(1.0, 6.0)
2.6  1.0 (138)
(1.0, 5.0)
0.838
CHF 63/269 (23.4%) 32/138 (23.2%) 0.958
History of hypertension 238/269 (88.5%) 134/138 (97.1%) 0.003
Age $75 yrs 140/269 (52.0%) 78/138 (56.5%) 0.391
Diabetes 91/269 (33.8%) 41/138 (29.7%) 0.401
Previous TIA/ischemic stroke 74/269 (27.5%) 39/138 (28.3%) 0.873
AF pattern 0.873
Paced 7/269 (2.6%) 5/138 (3.6%)
Paroxysmal 131/269 (48.7%) 71/138 (51.4%)
Permanent 42/269 (15.6%) 22/138 (15.9%)
Persistent 85/269 (31.6%) 39/138 (28.3%)
Unknown 4/269 (1.5%) 1/138 (0.7%)
LVEF, % 55.4  10.0 (268)
(30.0, 80.0)
56.0  9.8 (137)
(30.0, 77.0)
0.571
CHA2DS2-VASc score (categorical) 0.300
1 0/269 (0.0%) 1/138 (0.7%)
2 19/269 (7.1%) 7/138 (5.1%)
3 78/269 (29.0%) 44/138 (31.9%)
4 95/269 (35.3%) 35/138 (25.4%)
5 50/269 (18.6%) 37/138 (26.8%)
6 20/269 (7.4%) 12/138 (8.7%)
7 6/269 (2.2%) 3/138 (2.2%)
8 1/269 (0.4%) 0/138 (0.0%)
CHA2DS2-VASc score (continuous) 3.8  1.2 (268)
(1.0, 8.0)
3.9  1.2 (137)
(1.0, 7.0)
0.467
Values are mean  SD (n, minimum, maximum) or n/N (%). The p values are based on t tests for continuous
variables and chi-square tests for other variables.
AF ¼ atrial ﬁbrillation; CHADS2 ¼ congestive heart failure, hypertension, age >75 years, diabetes mellitus, and
previous stroke/transient ischemic attack; CHA2DS2-VASc¼ CHADS2 variables but also incorporating age 65 to 74
years, female sex, and vascular disease; CHF ¼ congestive heart failure; LVEF ¼ left ventricular ejection fraction;
TIA ¼ transient ischemic attack.
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4PROCEDURES. The Watchman device was implanted
as previously described (17). It is a self-expanding,
nickel titanium (nitinol)-framed structure ranging in
diameter from 20 to 33 mm to accommodate varying
LAA anatomy and size. The device has ﬁxation barbs to
minimize embolization and a permeable polyester
fabric cover. Implantation was performed via a trans-
septal approach and was guided by ﬂuoroscopy and
transesophageal echocardiography (TEE) to verify
proper positioning and stability. On rare occasions,
intracardiac echocardiography was used during im-
plantation (although it was not required).
After implantation, patients were treated with
warfarin (Coumadin, Bristol-Myers Squibb, New York,
New York) and aspirin (81 mg) for 45 days, the same
regimen used in the PROTECT AF trial (17) to prevent
large thrombus formation on the device during its
endothelialization. TEE was performed at 45 days’,
6 months’, and 12 months’ follow-up to assess device
stability, document optimal ostial position, and
evaluate the presence and degree of residual peri-
device ﬂow. If the 45-day TEE documented either
complete closure of the LAA, or if residual peridevice
ﬂow was <5 mm in width and there was no deﬁnite
visible large thrombus on the device, warfarin was
discontinued. After discontinuation of warfarin, only
daily clopidogrel 75 mg and aspirin 81 to 325 mg were
prescribed until the 6-month follow-up visit, at which
time clopidogrel was discontinued and aspirin alone
was continued indeﬁnitely (Fig. 1).
Control patients received warfarin during the dura-
tion of the studywith a target international normalized
ratio between 2.0 and 3.0. This ratio was monitored at
least every 2 weeks for 6 months and at least 1 month
thereafter to assess the need for dose adjustment.
Follow-up visits occurred at 45 days, 6 months,
9 months, and biannually thereafter. Neurologic
assessment was performed at baseline, 12 months,
and 24 months, as well as whenever a neurologic
event was suspected or had occurred.
STATISTICAL ANALYSIS. Statistical analysis was
performed by using data from the previously reported
randomized PROTECT AF trial of LAA closure
compared with warfarin with a Bayesian model and
adaptive sample size methods (21). Data on endpoints
from PROTECT AF subjects meeting the inclusion/
exclusion criteria for PREVAIL were used in a histor-
ical previous distribution, with 50% discounting to
reduce the inﬂuence of the earlier data. The primary
study model was a piecewise exponential model with
4 time periods (0 to 7, 8 to 60, 61 to 182, and $183
days) and conjugate gamma priors with parameters
based on the follow-up time and events from PRO-
TECT AF. The primary treatment comparison was
TABLE 2 Coprimary Efﬁcacy Endpoint Results (Stroke, Systemic Embolism,
or Cardiovascular/Unexplained Death)
Device
18-Month Rate
Control
18-Month Rate
18-Month Rate
Ratio (95% CrI)
Rate Ratio Noninferiority
Criterion
0.064 0.063 1.07 (0.57, 1.89) 95% CrI upper bound <1.75
CrI ¼ credible interval.
TABLE 3 Coprimary Efﬁcacy Endpoint Observed Events by Type: PREVAIL Subjects Only
(Intention-to-Treat)*
Device Group Control Group
No. of
Events
% of
Subjects
% of
Endpoints
No. of
Events
% of
Subjects
% of
Endpoints
Ischemic stroke 5 1.9 35.7 1 0.7 25.0
Hemorrhagic stroke 1 0.4 7.1 0 0.0 0.0
Death (cardiovascular/unexplained) 7 2.6 50.0 3 2.2 75.0
Systemic embolism 1 0.4 7.1 0 0.0 0.0
*Endpoint analysis was based on the initial event per-patient even if a patient experienced multiple events.
PREVAIL¼Watchman LAAClosure Device in PatientsWith Atrial Fibrillation Versus Long TermWarfarin Therapy.
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5made by calculating, via Monte Carlo simulation, the
posterior distributions for the 18-month event rates
and calculating the probability of noninferiority. All
follow-up information from the post–182-day period
was used in the ﬁnal hazards analysis in the model,
contributing to the calculation of the probability of
18-month events.
For the primary efﬁcacy endpoint, the rate ratio of
18-month event rates of the device and control groups
were compared, and a risk ratio criterion (treatment
over control) of 1.75 was used to establish non-
inferiority. The late-ischemic primary endpoint was
deﬁned to isolate periprocedural events of ischemic
stroke and SE >7 days’ post-randomization. The sec-
ond endpoint was based on a 1-tailed test, in which
the null hypothesis would be rejected if either the
ratio or the difference between rates in the random-
ized groups satisﬁed the noninferiority criteria. No
adjustment was made for multiple comparisons. A
composite criterion for either the risk ratio or risk
difference was used, with criterion of the 95% upper
credible interval (CrI) <2.0 and <0.0275, respectively.
The risk ratio criterion was used to mirror and expand
on the criterion for the ﬁrst endpoint. However, as the
second endpoint of late stroke/SE is rarer than the
ﬁrst composite endpoint, the risk difference was
established as part of the criteria for the second
endpoint to provide adequate power. Achievement of
either of these 2 criteria would satisfy noninferiority.
The sample size was determined based on an adap-
tive interim analysis in which the predictive proba-
bilities of success for the 2 endpoints were calculated;
enrollment was to be stopped early if the predictive
probability of success at an interim analysis exceeded
0.95. Enrollment continued to the full maximum
planned sample size because this threshold was not
achieved during enrollment. Per the adaptive design,
follow-up continued for 6 months after completion of
enrollment, at which time the ﬁnal analysis occurred.
The early safety primary endpoint was speciﬁc to the
device arm and was analyzed simultaneous to the
ﬁnal analysis of the ﬁrst 2 endpoints described earlier.
This model was a beta-binomial model with an his-
torical prior, based on data from the device subjects
in PROTECT AF and CAP (Continued Access PROTECT
AF Registry) studies. This method became the per-
formance goal for comparison (19). The CAP study
was conducted similarly to PROTECT AF in that pa-
tients were treated with warfarin up until the 45-day
TEE. This early safety primary endpoint was not
incorporated into the Bayesian adaptive design.
However, because of those safety endpoints, a safety
guideline was used. The statistical criterion for suc-
cess was a 1-sided 95% upper credible boundof <2.67% to ensure that the rate of procedural safety
events was sufﬁciently low. All endpoints for the
study are based on 1-sided tests.
RESULTS
PREVAIL enrolled 407 patients; 269 were randomized
to the device group and 138 to the control group.
Baseline characteristics were similar between the 2
arms: mean age 74.0  7.4 years versus 74.9  7.2
years (device vs. control) (p ¼ 0.260); CHADS2 score
2.6  1.0 versus 2.6  1.0 (p ¼ 0.838); and CHA2DS2-
VASc score (using the CHADS2 variables but also
incorporating age 65 to 74 years, female sex, and
vascular disease) 3.8  1.2 versus 3.9  1.2 (p ¼ 0.467)
(Table 1). As pre-speciﬁed, 38.8% of patients were
enrolled at new sites, and 39.1% of procedures were
performed by new operators. The device was suc-
cessfully implanted in 95.1% of the patients in whom
it was attempted (252 of 265). There were 4 patients in
whom an implant was not attempted, even though
they had been randomized to the device arm group.
Reasons for the aborted attempts were that the
patient did not stop anticoagulation before the pro-
cedure (n ¼ 1), pre-implant TEE revealed a new LAA
thrombus (n ¼ 1), and LAA size and shape were not
optimal for the device (n ¼ 2). All patients had a
minimum follow-up of 6 months. For randomized
subjects, the mean follow-up was 11.8  5.8 months,
and the median follow-up was 12.0 months (range:
0.03 to 25.9 months). After successful implantation,
92.2% (227 of 246), 98.3% (235 of 239), and 99.3% (141
of 142) of patients were able to discontinue warfarin
after 45 days, 6 months, and 12 months, respectively.
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FIGURE 2 Kaplan-Meier Curve: Freedom From First Primary Endpoint (Intention-to-Treat)
Primary efﬁcacy rates for Watchman (solid line) versus warfarin (dotted line) in the intention-to-treat population show similarly high 18-month
event-free rates.
TABLE 4 Late-Ischem
Device
18-Month
Rate
Control
18-Month
Rate
0.0253 0.0200
Abbreviations as in Tables
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6PRIMARY EFFICACY ENDPOINT. The 18-month event
rates of the ﬁrst primary efﬁcacy endpoint were
similar and expectedly low in both the device group
(0.064) and the control group (0.063), yielding a
mean 18-month rate ratio of 1.07 (95% CrI: 0.57 to
1.89). The upper bound of 1.89 was not lower than the
pre-speciﬁed noninferiority margin of 1.75 predeﬁned
in the statistical analysis plan. Therefore, statistical
noninferiority was not achieved (Tables 2 and 3).
Kaplan-Meier estimates for freedom from the primary
efﬁcacy endpoint are presented in Figure 2. One
stroke or SE occurred with warfarin (0.71%/patient-
year), despite a mean CHADS2 score of 2.6.
LATE-ISCHEMIC PRIMARY EFFICACY ENDPOINT. The rate
of stroke or SE >7 days after randomization (Table 4)
was 0.0253 for the device group and 0.0200 for the
control group (18-month risk difference 0.0053 [95%
CrI: –0.0190 to 0.0273]). Because the 95% upper CrI of
the risk difference was <0.0275, noninferiority of the
device group to the control group was achieved.
Kaplan-Meier estimates for this endpoint are pre-
sented in Figure 3.ic Coprimary Endpoint: PREVAIL Subjects Only (Intention-to-Treat)
18-Month
Rate Ratio
(95% CrI)
Rate Ratio
Noninferiority
Criterion
18-Month Rate
Difference
(95% CrI)
Rate Difference
Noninferiority
Criterion
1.6 (0.5 to 4.2) 95% CrI upper
bound <2.0
0.0053 (–0.0190
to 0.0273)
95% CrI upper
bound <0.0275
2 and 3.EARLY SAFETY PRIMARY ENDPOINT. The primary
safety endpoint was evaluated only in the device
group. CrIs were calculated from a Bayesian model
that used PROTECT AF and the CAP Registry as prior
sources and calculation of ﬁrst event per subject.
Success for this endpoint was deﬁned as being ach-
ieved if the percentage of patients experiencing one
of the events was statistically less than the perfor-
mance goal, deﬁned as 2.67% with an upper bound of
the 1-sided 95% CrI less than the performance goal
(Table 5). There were only 6 events meeting this
safety primary endpoint in the 269 patients with de-
vice implantation. Accordingly, 2.2% of subjects
experienced an event, and the 1-sided 95% CrI upper
bound was 2.652%; therefore, success for this
endpoint was achieved.
COMPARISON WITH EARLIER STUDIES. An early
procedural hazard was of particular concern in the
initial experience with LAA occlusion (19); therefore,
several pre-speciﬁed comparisons were performed to
assess the evolution of safety events over the course
of the studies of the Watchman device. A total of
1,298 patients were treated with the Watchman de-
vice in 3 studies (PROTECT AF, CAP, and PREVAIL).
As per the protocol design, PREVAIL and CAP patients
were at higher risk (Table 6) than PROTECT AF pa-
tients, with older age (74.0  7.4 years and 74.0  8.3
years vs. 71.7  8.8 years [p < 0.001]) and a higher
CHADS2 score (2.6  1.0 and 2.5  1.2 vs. 2.2  1.2
[p < 0.001]). Compared with other trials, PREVAIL
had more patients >75 years of age. PREVAIL patients
TABLE 5 Safety Coprimary Endpoint Results and Events by Type
(Intention-to-Treat): Device Group Only
% (n/N) 95% CrI
Safety primary endpoint results 2.2% (6/269) 2.652%
No. of Events % of Subjects
Safety events by type
Device embolization 2 0.7
Arteriovenous ﬁstula 1 0.4
Cardiac perforation 1 0.4
Pericardial effusion with cardiac tamponade 1 0.4
Major bleed requiring transfusion 1 0.4
Abbreviation as in Table 2.
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FIGURE 3 Kaplan-Meier Curve: Freedom From Second Primary Endpoint Event (Intention-to-Treat)
Late-ischemic events (stroke or systemic embolism >7 days’ post-randomization) for Watchman (solid line) versus warfarin (dotted line) in the
intent-to-treat population demonstrated noninferiority for the rate difference endpoint.
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7also had a higher incidence of diabetes mellitus
and a higher incidence of previous stroke/transient
ischemic attack.
Procedural success, deﬁned as device deployment
and release, increased from 90.9% in PROTECT AF to
95.1% in PREVAIL (p ¼ 0.04). To evaluate the com-
plications in PREVAIL by using the identical deﬁni-
tions used in PROTECT AF, we assessed all 7-day
procedure-related complications, deﬁned as a com-
posite of cardiac perforation, pericardial effusion
with tamponade, ischemic stroke, device emboliza-
tion, and other vascular complications occurring in
the ﬁrst 7 days after implant. These decreased from
8.7% in PROTECT AF to 4.2% in PREVAIL (p ¼ 0.004).
Pericardial effusions requiring surgical repair also
decreased from 1.6% to 0.4% (p ¼ 0.027); effusions
requiring pericardiocentesis or a pericardial window
were numerically lower in PREVAIL (1.5% [4 of 265]
vs. PROTECT AF 2.9% [13 of 449]; p ¼ 0.36), although
the absolute number of events was small. Procedural
and device-related strokes decreased, from 1.1% in
PROTECT AF to 0.4% in PREVAIL (p ¼ 0.007). Device
embolization was infrequent, occurring in only 4 pa-
tients (2 in PROTECT AF, 2 in PREVAIL) and was not
statistically signiﬁcantly different across the studies
(Table 7).
An important component of this analysis was
evaluation of the learning curve with new versus
experienced operator sites. Implantation success was
achieved in 95.1% overall and in 96.3% with experi-
enced operators versus 93.2% with new operators(p ¼ 0.256); there were no signiﬁcant differences in
complication rates between the 2 groups.
DISCUSSION
The PREVAIL trial adds information to the initial
pivotal PROTECT AF trial by using a Bayesian non-
inferiority design approach (21). The major ﬁndings of
the trial were: 1) LAA occlusion with the Watchman
device was not noninferior to warfarin for the primary
efﬁcacy composite endpoint of all-cause stroke, car-
diovascular or unexplained death, and SE, although
the event rates with warfarin were signiﬁcantly lower
than expected, affecting the ability of the study to
establish noninferiority; 2) the Watchman device
was noninferior to warfarin for the occurrence of
late ischemic events, such as ischemic stroke or SE
TABLE 6 Demographic Characteristics of Patients Receiving the Watchman Device in PROTECT AF, CAP, and PREVAIL
PROTECT AF
(n ¼ 463)
CAP
(n ¼ 566)
PREVAIL
(n ¼ 269) p Value
Age, yrs 71.7  8.8 (46.0, 95.0) 74.0  8.3 (44.0, 94.0) 74.0  7.4 (50.0, 94.0) <0.001
Male 326/463 (70.4%) 371/566 (65.5%) 182/269 (67.7%) 0.252
CHADS2 score (continuous) 2.2  1.2 (1.0, 6.0) 2.5  1.2 (1.0, 6.0) 2.6  1.0 (1.0, 6.0) <0.001
CHADS2 risk factors
CHF 124/463 (26.8%) 108/566 (19.1%) 63/269 (23.4%)
Hypertension 415/463 (89.6%) 503/566 (88.9%) 238/269 (88.5%)
Age $75 yrs 190/463 (41.0%) 293/566 (51.8%) 140/269 (52.0%)
Diabetes 113/463 (24.4%) 141/566 (24.9%) 91/269 (33.8%)
Stroke/TIA 82/463 (17.7%) 172/566 (30.4%) 74/269 (27.5%)
Values are mean  SD (minimum, maximum) or n/N (%).
CAP ¼ Continued Access PROTECT AF; PROTECT AF ¼ Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation;
other abbreviation as in Tables 1 and 3.
TABLE 7
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8occurring after theﬁrst 7 days following randomization
to isolate the effect of early periprocedural events from
a longer term mechanism of action; and 3) the
Watchman procedure met the pre-speciﬁed success
criterion for safety events, evenwith a large proportion
of operators without previous experience implanting
the device within a higher risk patient population
(Central Illustration).
The relationship between AF and stroke has been
the subject of exhaustive study. Stroke in this setting
has been predominantly thromboembolic in nature,
secondary to LAA thrombus. This pathophysiology
led to the widespread application of anticoagulant
therapy, initially with warfarin, which has been
proven superior to aspirin for stroke prevention (22).
Multiple problems with warfarin, however, have been
identiﬁed, including bleeding, contraindications to
its application, patient compliance, and the need for
routine monitoring (23–26). Thus, it is estimated that
anticoagulation is not currently used in up to 50% of
eligible AF patients, which led to the development of
new oral anticoagulants (NOACs), whose efﬁcacy
have been established in randomized clinical trials
(7–9). The rates of bleeding with approved doses ofComparison of Outcomes in Device Patients in PROTECT AF,
PREVAIL
PROTECT AF CAP PREVAIL p Value
ccess 90.9 94.3 95.1 0.04
procedural complications 8.7 4.2 4.5 0.004
ial effusion requiring surgery 1.6 0.2 0.4 0.03
ial effusion with pericardiocentesis 2.4 1.2 1.5 0.318
re-related strokes 1.1 0.0 0.7 0.02
mbolization 0.4 0.2 0.7 0.368
ns as in Tables 3 and 6.NOACs are either similar to warfarin, or, in the case of
apixaban, lower, but rivaroxaban and dabigatran had
an increased risk of gastrointestinal bleeding. In older
patients or those with renal dysfunction, the bleeding
risks associated with dabigatran were equal or greater
than warfarin (27). This bleeding risk, combined with
the perceived absolute or relative contraindications
by the patient or physician, as well as issues with
long-term compliance, cost, and the lack of widely
available antidotes, represent substantial challenges
for the management of stroke prevention in patients
with AF (28).
In patients with NVAF, the LAA is the location of
the thrombus felt to be the putative cause of stroke
in approximately 90% of cases (10). In the pivotal
PROTECT AF trial, comparing LAA occlusion with
warfarin, placement of the Watchman device was
noninferior for prevention of the primary composite
endpoint of ischemic or hemorrhagic stroke, cardio-
vascular or unexplained death, and SE (17). An early
safety hazard was identiﬁed: an increase in peri-
procedural events of pericardial effusions, which did
not result in mortality but did prolong hospital stay.
A risk for periprocedural stroke was also identiﬁed,
usually the result of air embolization during catheter
placement.
Longer term follow-up of PROTECT AF has
conﬁrmed the efﬁcacy of LAA occlusion. At a mean
follow-up of 2.3  1.1 years, the primary efﬁcacy
endpoint remained noninferior for device (3.0 vs. 4.3
[per 100 patient-years]; rate ratio 95% CrI: 0.44 to
1.30; probability of noninferiority >0.999) (18). At 45
months of follow-up, LAA occlusion was superior to
warfarin for the primary composite efﬁcacy endpoint.
At 45 months, the primary safety endpoint was non-
inferior for the device group because of the continued
increase in adverse safety events with warfarin,
ARISTOTLE
ROCKET AF
RE-LY
PREVAIL
Rate Per Patient-years
0.1
0.70
1.70
2.20
1.60
101
FIGURE 4 Ischemic Stroke Rates in Warfarin Control Groups
Control (warfarin) ischemic stroke rates per 100 patient-years in new oral
anticoagulant NOAC trials and the PREVAIL (Watchman LAA Closure Device in
Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) trial. The
relatively small sample size and an unexpected overperforming control group
could have contributed to the results seen in the ﬁrst primary endpoint.
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9emphasizing the long-term hazard of anticoagulants
that could be avoided with mechanical intervention
(29). Within the early and late PROTECT AF experi-
ence, as well as the CAP Registry, procedural/device-
related safety events (including pericardial effusions)
declined signiﬁcantly, suggesting that the procedural
safety of Watchman implantation improved with
increasing experience. The fact that the acute proce-
dural success and complication rates continued to be
low even among new centers and new operators
suggest that the knowledge gained during the initial
experience could be successfully transferred to new
sites and operators.
Against this background of improving results of
LAA occlusion compared with control warfarin, and
because of initial concerns about trial design and
endpoint deﬁnition, the U.S. Food and Drug Admin-
istration requested this second trial (PREVAIL). A
Bayesian analysis design was agreed upon using
priors from PROTECT AF and CAP. Trial design
included a higher risk group, which was achieved in
that PREVAIL patients were older and had higher
CHADS2 and CHA2DS2VASc scores. Within PREVAIL,
there were 3 primary endpoints, each aimed at
addressing particular concerns. With the ﬁrst pri-
mary efﬁcacy endpoint (a composite of all-cause
stroke, cardiovascular or unexplained death, and
SE), the absolute event rates were similar with LAA
occlusion and warfarin, but noninferiority was not
met, given the wide 95% CrIs. One potential reason
for this ﬁnding was the substantially lower-than-
expected number of events, particularly in the con-
trol group: the rate of stroke or SE with warfarin was
signiﬁcantly less than in other contemporary trials of
stroke prevention in AF that had included a warfarin
control (RE-LY [Randomized Evaluation of Long
Term Anticoagulant Therapy], ARISTOTLE [Apixaban
for the Prevention of Stroke in Subjects With Atrial
Fibrillation], and ROCKET AF [Rivaroxaban Once-
daily Oral Direct Factor Xa Inhibition Compared
With Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation]) (7–9). In
these trials, stroke and SE rates in the warfarin con-
trol arms were 1.7, 1.6, and 2.2 per 100 patient-years,
respectively. In contrast, in PREVAIL, ischemic
stroke in the warfarin control group was 0.71 per
100 patient-years (Fig. 4). This unexpected, over-
performing control group reduced the ability to
establish noninferiority given the statistical trial
design. One partial explanation for this ﬁnding may
be related to the time-in-therapeutic range, which
was 68% for PREVAIL versus 64%, 62%, and 55%,
respectively, for RE-LY (7), ARISTOTLE (8), and
ROCKET AF (9). The lower rate of stroke also mayhave occurred in the present trial given the relatively
smaller sample size.
The late-ischemic primary efﬁcacy endpoint
excluded events occurring within 7 days of ran-
domization and was designed to look at speciﬁc
device performance once implanted in subsequently
reducing ischemic stroke or SE. This achieved the
pre-speciﬁed noninferiority criteria, supporting the
contention that LAA occlusion can prevent longer
term ischemic events in the absence of chronic
anticoagulation.
The third primary endpoint assessed the effect of
adding early safety signals with events within the
ﬁrst 7 days or during the index hospitalization, based
on the PROTECT AF ﬁnding that device-related safety
events occurred within the ﬁrst 7 days and were
procedurally related for the most part. This third
endpoint used priors from both PROTECT AF and the
CAP Registry and met its pre-speciﬁed criterion for
success. In the safety endpoint analysis, a frequentist
approach identiﬁed that the composite of all 7-day
periprocedural complications had decreased signiﬁ-
cantly from PROTECT AF to PREVAIL; both pericar-
dial effusions requiring surgical treatment and stroke
were signiﬁcantly less frequent.
STUDY LIMITATIONS. In the PROTECT AF and PRE-
VAIL trials, patients were required to be candidates
for long-term anticoagulation to facilitate randomi-
zation against a control group treated with warfarin.
The present trial does not address the safety and ef-
ﬁcacy of LAA occlusion in patients in whom anti-
coagulation is believed to be either relatively or
CENTRAL ILLUSTRATION Design and Outcomes of the PREVAIL Trial
The multicenter, randomized controlled PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin
Therapy) trial assessed the safety and efﬁcacy of left atrial appendage (LAA) closure with the Watchman device compared with warfarin in
patients with nonvalvular atrial ﬁbrillation (paroxysmal, persistent, or permanent) with a CHADS2 (congestive heart failure, hypertension, age
>75 years, diabetes mellitus, and previous stroke/transient ischemic attack) score $2. PREVAIL enrolled 407 patients; 269 were randomized to
the device group and 138 to the control group. After successful implantation, 92.2%, 98.3%, and 99.3% of patients were able to discontinue
warfarin after 45 days, 6 months, and 12 months, respectively. The 18-month event rates of the ﬁrst primary efﬁcacy endpoint were similar and
expectedly low in both the device (0.064) and control (0.063) groups, yielding a mean 18-month rate ratio of 1.07. INR ¼ international
normalized ratio.
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10absolutely contraindicated. This population was
evaluated in the observational ASAP (ASA Plavix)
study, but there are no randomized data available
(30). Also, neither PREVAIL nor PROTECT AF
compared the safety and efﬁcacy of Watchman with
NOACs. It is also unknown whether the loss of the
mechanical function of the LAA after occlusion may
have any clinical signiﬁcance. Finally, due to the low
overall trial event rates, there was limited power with
the planned sample size in PREVAIL to establish
noninferiority for the primary efﬁcacy endpoint,
which was based on a rate ratio.
CONCLUSIONS
The PREVAIL trial documented the following ﬁnd-
ings in patients with NVAF at risk for stroke: 1) pro-
cedural complications occurring after Watchman
LAA occlusion were infrequent and signiﬁcantly im-
proved compared with the PROTECT AF trial;
2) Watchman LAA occlusion was noninferior to
chronic warfarin for the prevention of stroke and SEbeginning 1 week after randomization, consistent
with the hypothesis that the LAA is the nidus for
embolism in AF; and 3) the primary efﬁcacy endpoint
of early and late events was similar and did not
achieve noninferiority with the Watchman device.
Overall event rates were lower than expected, which
may have contributed to this last ﬁnding. The totality
of the data now available on the procedural safety
and long-term efﬁcacy for the Watchman device
support that closure of the LAA remains a reasonable
alternative to chronic long-term warfarin therapy for
prevention of stroke/systemic embolization in pa-
tients with NVAF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: In patients
with NVAF, the LAA is the main source of thromboembolism.
In this setting, stroke is usually highly morbid, often fatal,
and associated with increased risk of recurrent events.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Oral antico-
agulation with warfarin has been the traditional approach for
stroke prevention in these patients who are deemed to be at
increased risk. For various reasons, including bleeding and
the need for routine coagulation monitoring, warfarin is used
in only approximately 50% of patients. Newer oral anticoag-
ulants have been developed that have advantages relative
to warfarin, but they carry certain disadvantages, such as an
increased risk of gastrointestinal bleeding and a lack of proven
reversal strategies.
COMPETENCY IN MEDICAL KNOWLEDGE 3: Randomized
trials of patients with NVAF have documented that LAA oc-
clusion performed with an implantable device is noninferior to
warfarin for stroke prevention.
COMPETENCY IN PATIENT KNOWLEDGE: In patients
with an elevated risk of stroke in the setting of NVAF, in whom
there is concern about the long-term risk of bleeding with
warfarin therapy, the use of an LAA occlusion device
(Watchman) may be considered.
TRANSLATIONAL OUTLOOK: Previous studies using path-
ologic, surgical, and echocardiographic data have suggested
that the LAA was the source of thromboembolism in patients
with NVAF. The randomized PROTECT AF and PREVAIL trials
have conﬁrmed that occlusion of the LAA by the Watchman
device was noninferior to the conventional approach of using
systemic warfarin anticoagulation.
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